ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

AudioMedica News
AudioMedica News
ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up
Loading
/
Jack Cuzick
Jack Cuzick

JACK CUZICK, Wolfson Institute of Preventive Medicine, London
New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continued superiority of the aromatase inhibitor. Among other things, the data now show a benefit in the time to distant recurrence. Derek Thorne heard more from Jack Cuzick, of the Wolfson Institute of Preventive Medicine in London.

ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071214_jack_cuzick.mp3]

Further reading

Sign up for AudioMedica.com news

* = required field
Speciality